- Current report filing (8-K)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

June 18, 2009

 

Date of Report (Date of earliest event reported)

OSI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		0-15190		13-3159796
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

41 Pinelawn Road
Melville, NY 11747

 

(Address of principal executive offices)

[phone]

 

(Registrant’s telephone number, including area code)

N/A

 

(Former name or former address,
if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a- 12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Item 8.01. Other Events.

     On June 18, 2009, OSI Pharmaceuticals, Inc. (“OSI”) received a second, non-final office action notice from the U.S. Patent and Trademark Office (“U.S. PTO”) regarding OSI’s application for a reissue of OSI’s composition of matter patent for Tarceva ^® (erlotinib), U.S. Patent No. 5,747,498 (the ‘498 patent). Other than the rejection of two claims as being indefinite due to the improper format of the claims (i.e., unmatched brackets), there were no patentability rejections of the claimed subject matter over prior art. The office action also sets forth a rejection of all claims based upon a defective oath or declaration. OSI is responding to the U.S. PTO’s comments and remains optimistic that it will have the reissue process substantially completed by the end of 2009.

-2-

---

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2009	OSI PHARMACEUTICALS, INC.
	By:	/s/ Barbara A. Wood
		Barbara A. Wood
		Senior Vice President, General Counsel and Secretary

-3-